Tesamorelin

Estimated Market Price

$70 – $120

Estimated for 10 mg vial · Based on verified supplier pricing

FDA-approved GHRH analog for visceral fat reduction. Targets deep abdominal fat, supports cognitive function, and stimulates natural GH release.

How it works

Stimulates natural pulsatile GH release through the GHRH receptor, with a chemical modification that makes it more stable than sermorelin. Specifically targets visceral belly fat while preserving subcutaneous fat.

Growth Hormone

Weight Management

What to Expect

Week 1–2 GH release stimulated; initial metabolic activation begins. No visible change yet; GH release activating.

Week 3–6 Visceral fat reduction measurable; abdominal circumference decreasing. Belly area feels tighter; waistband getting looser.

Week 7–12 Significant VAT reduction; body composition notably improved. Significant reduction in belly fat; midsection visibly flatter.

Week 13+ Sustained benefits with continued dosing; labs for monitoring. Sustained midsection leanness; core looks defined.

Verified Suppliers

For research purposes only. These suppliers have been independently verified by PepSpace. We do not process sales directly.

PepSpace is not affiliated with any listed supplier

LarnaLabs Verified Supplier · larnalabs.com

NXPeptides Verified Supplier · nxpeptides.com

BioSynth Verified Custom Batch Supplier · biosynth.com

Peptide Sciences Unavailable · peptidesciences.com

Protocol & Dosage

Typical Dosage 1–2 mg SC daily, AM (fasted)

Administration Subcutaneous injection

Schedule Once daily in the morning, fasted

Protocol Duration 12+ weeks

Half-Life ~26 minutes

Side Effects & Safety

Tolerability Profile Mild

Generally well tolerated; side effects are mild and transient

Common Side Effects

Injection site reactions (erythema, pruritus)~9%
Joint pain (arthralgia)~4%
Pain in extremity~3%
Peripheral edema~3%
Muscle pain (myalgia)~2%

Less Common

Nauseaoccasional
Paresthesia (tingling, numbness)occasional
Hyperglycemiaoccasional
Headacheoccasional

Rare / Serious

Hypersensitivity reactionsrare
Fluid retentionrare

Discontinue If

Signs of elevated blood sugar (increased thirst, frequent urination)
Persistent joint pain or carpal tunnel symptoms
Severe allergic reaction

Contraindications

Active cancer or malignancy
Disruption of hypothalamic-pituitary axis (surgery, radiation)
Pregnancy or breastfeeding
Known hypersensitivity to tesamorelin or mannitol

Data note: FDA-approved (Egrifta, 2010) for HIV lipodystrophy. Well-characterized safety profile from Phase III trials.

Always consult a qualified healthcare professional before use. This information is for research reference only and does not constitute medical advice.

Ask about Tesamorelin

How to Apply

Gather

Peptide vial, BAC water, alcohol swabs, insulin syringe

Sanitize

Wipe tops of both vials with alcohol swabs

Draw

Pull 1–2 mL of BAC water into syringe

Add Water

Release water slowly along vial wall, not directly on powder

Swirl

Roll between palms until dissolved. Never shake.

Store

Refrigerate 2–8°C, use within 30 days

Frequently Asked Questions

Yes. Bacteriostatic water (BAC water) is required to reconstitute lyophilized (freeze-dried) peptides. It contains 0.9% benzyl alcohol which prevents bacterial growth, keeping your reconstituted peptide safe for multiple uses over up to 30 days.

Unreconstituted: store at -20°C (freezer) for long-term, or 2–8°C (fridge) for short-term. After reconstitution: always refrigerate at 2–8°C and use within 30 days. Keep away from direct sunlight.

Results vary by individual and protocol. In research settings, measurable effects are typically observed within 1–4 weeks depending on the specific peptide, dosage, and application. Consult a qualified professional for guidance.

Verified suppliers typically include a full third-party COA verifying purity (99%+), identity, and sterility. We recommend only sourcing from vendors that provide batch-specific testing data.

We list verified suppliers above that have been independently reviewed for product quality, testing transparency, and shipping reliability. Always verify COA data before sourcing.

Compound Profile

Scientific data & classification for Tesamorelin

Also Known As Egrifta, TH9507, Tesamorelin Acetate

Classification Modified GHRH Analog · Growth Hormone Releasing

Sequence Trans-3-hexenoic acid-modified GHRH(1-44)NH₂ (44 aa + modification)

Molecular Formula C₂₂₁H₃₆₆N₇₂O₆₇S

Molecular Weight 5,135.87 Da

CAS Number 218949-48-5

Half-Life ~26 minutes

Origin Synthetic GHRH analog with N-terminal trans-3-hexenoic acid

Administration Subcutaneous injection

Status FDA Approved (2010) - HIV-associated lipodystrophy

Mechanism of Action Stimulates natural pulsatile GH release through the GHRH receptor, with a chemical modification that makes it more stable than sermorelin. Specifically targets visceral belly fat while preserving subcutaneous fat.

Research Overview Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid native GHRH sequence modified with a trans-3-hexenoic acid moiety conjugated to the N-terminal tyrosine residue. Developed by Theratechnologies Inc. in Montreal, Canada, tesamorelin received FDA approval in November 2010 under the trade name Egrifta for the reduction of excess abdominal fat (visceral adipose tissue) in HIV-infected patients with lipodystrophy - a metabolic complication affecting an estimated 20-35% of patients on antiretroviral therapy characterized by abnormal fat redistribution with visceral fat accumulation, subcutaneous fat loss, dyslipidemia, and insulin resistance. The trans-3-hexenoic acid modification at the N-terminus provides enhanced stability against aminopeptidase degradation while maintaining full agonist activity at the GHRH receptor, resulting in a half-life of approximately 26 minutes following subcutaneous injection - substantially longer than native GHRH but shorter than the DAC-modified analogs. The pivotal Phase III clinical trials demonstrated that tesamorelin treatment produced a statistically and clinically significant reduction in trunk fat of approximately 15-18% as measured by CT scan, with notable improvements in patient-reported body image distress scores and triglyceride levels. Importantly, the reduction in visceral adipose tissue occurred without significant changes in subcutaneous fat, limb fat, glucose tolerance, or overall body weight - indicating a highly selective effect on the visceral fat depot that distinguishes tesamorelin from general weight loss interventions. Research has increasingly focused on tesamorelin's potential for treating non-alcoholic fatty liver disease (NAFLD/NASH), particularly in the HIV population where hepatic steatosis prevalence exceeds that of the general population. A randomized controlled trial published in the Lancet HIV demonstrated significant reductions in hepatic fat fraction and NASH resolution rates, and larger trials are underway. The compound's FDA-approved status has facilitated broader clinical research applications beyond HIV-associated lipodystrophy.

Citations

Published findings on Tesamorelin from peer-reviewed journals.

Tesamorelin, a human growth hormone releasing factor analogue, improves visceral adipose tissue and metabolic parameters in HIV-infected patients

Falutz J, et al. • 2010 PubMed

Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy

Bedimo R • 2011 PubMed

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat

Stanley TL, et al. • 2015 PubMed